Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Julie Bellemans

3 Results

2022

One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer

Jonas SteenbruggeJulie BellemansNiels Vander ElstKristel DemeyereJosephine De VliegherTimothy PereraOlivier De WeverWim Van Den BroeckWard De SpiegelaereNiek Sanders et al.

A1 Journal Article in ONCOIMMUNOLOGY

2022

One cisplatin dose suffices to maintain anti-tumor immunity and enhances anti-PD-1 efficacy in an intraductal model for triple-negative breast cancer

Jonas SteenbruggeJulie BellemansNiels Vander ElstKristel DemeyereNiek SandersEvelyne Meyer

C3 Conference

2022

Progression of canine mammary tumors is associated with an immunosuppressed microenvironment

Jonas SteenbruggeJulie BellemansLennert HeirmanAurelie De RooverKristel DemeyereHilde De RoosterEvelyne Meyer

C3 Conference

2022